Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort

1. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol. 1998;72(9):7632–7 9696866

2. Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001;7(6):712–8 doi: 10.1038/89090 11385509

3. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003;187(4):683–6 doi: 10.1086/367989 12599087

4. de Mendoza C, Rodriguez C, Corral A, del Romero J, Gallego O, Soriano V. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. Clin Infect Dis. 2004;39(8):1231–8 doi: 10.1086/424668 15486849

5. VandeVijver D, Wensing A, Asjo B, Bruckova M, Jorgensen LB, Horban A, et al., editors. Selective transmission of drug resistance mutations. 14th International HIV Drug Resistance Workshop; Quebec City, Canada. June 7–11, 2005 [abstract #113].

6. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther. 2004;9(3):375–84 15259900

7. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002;76(4):1753–61 doi: 10.1128/JVI.76.4.1753-1761.2002 11799170

8. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther. 2004;9(3):415–21 15259904.

9. Blick G, Kagan RM, Coakley E, Petropoulos C, Maroldo L, Greiger-Zanlungo P, et al. The Probable Source of Both the Primary Multidrug-Resistant (MDR) HIV-1 Strain Found in a Patient with Rapid Progression to AIDS and a Second Recombinant MDR Strain Found in a Chronically HIV-1-Infected Patient. J Infect Dis. 2007;195(9):1250–9 doi: 10.1086/512240 17396993

10. Smith DM, Wong JK, Shao H, Hightower GK, Mai SH, Moreno JM, et al. Long-Term Persistence of Transmitted HIV Drug Resistance in Male Genital Tract Secretions: Implications for Secondary Transmission. J Infect Dis. 2007;196(3):356–60 doi: 10.1086/519164 17597449

11. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, Maenza J, et al. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS ONE. 2011;6(12):e28952. doi: 10.1371/journal.pone.0028952 22194957; PubMed Central PMCID: PMC3241703.

12. Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, Jessen H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS. 2005;19(16):1819–25 16227789

13. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis. 2009;199(5):693–701. doi: 10.1086/596736 19210162

14. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5(7):e158 18666824.

15. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, et al. Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. J Infect Dis. 2013;208(7):1102–12. Epub 2013/07/13. doi: 10.1093/infdis/jit310 23847055

16. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105(21):7552–7. Epub 2008/05/21. PubMed Central PMCID: PMC2387184. doi: 10.1073/pnas.0802203105 18490657

17. Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol. 2009;83(6):2715–27. Epub 2009/01/01. PubMed Central PMCID: PMC2648286. doi: 10.1128/JVI.01960-08 19116249

18. Rieder P, Joos B, Scherrer AU, Kuster H, Braun D, Grube C, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis. 2011;53(12):1271–9. Epub 2011/10/15. doi: 10.1093/cid/cir725 21998286

19. Gifford RJ, Rhee SY, Eriksson N, Liu TF, Kiuchi M, Das AK, et al. Sequence editing by Apolipoprotein B RNA-editing catalytic component and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS. 2008;22(6):717–25. PubMed Central PMCID: PMCPMC2946849. doi: 10.1097/QAD.0b013e3282f5e07a 18356601

20. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ, et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol. 2011;85(16):8359–67. Epub 2011/06/03. PubMed Central PMCID: PMC3147985. doi: 10.1128/JVI.02582-10 21632754

21. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125(4):257–64 8678387

22. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998;128(8):613–20 9537934

23. Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, Mayers D, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis. 2001;183(10):1466–75 doi: 10.1086/320189 11319682

24. Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000;181(1):121–31 doi: 10.1086/315202 10608758

25. Stekler J, Sycks BJ, Holte S, Maenza J, Stevens CE, Dragavon J, et al. HIV Dynamics in Seminal Plasma during Primary HIV Infection. AIDS Res Hum Retrovir. 2008;24(10):1269–74. doi: 10.1089/aid.2008.0014 18844461

26. Campbell MS, Mullins JI, Hughes JP, Celum C, Wong KG, Raugi DN, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS ONE. 2011;6(3):e16986. doi: 10.1371/journal.pone.0016986 21399681; PubMed Central PMCID: PMC3047537.

27. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79(15):9625–34. Epub 2005/07/15. PubMed Central PMCID: PMC1181593. doi: 10.1128/JVI.79.15.9625-9634.2005 16014925

28. Gantt S, Shetty AK, Seidel KD, Matasa K, Musingwini G, Woelk G, et al. Laboratory indicators of mastitis are not associated with elevated HIV-1 DNA loads or predictive of HIV-1 RNA loads in breast milk. J Infect Dis. 2007;196(4):570–6. Epub 2007/07/13. doi: 10.1086/519843 17624843

29. Deng W, Maust BS, Westfall DH, Chen L, Zhao H, Larsen BB, et al. Indel and Carryforward Correction (ICC): a new analysis approach for processing 454 pyrosequencing data. Bioinformatics. 2013;29(19):2402–9. Epub 2013/08/01. PubMed Central PMCID: PMC3777116. doi: 10.1093/bioinformatics/btt434 23900188

30. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4(3):e4724. doi: 10.1371/journal.pone.0004724 19266092; PubMed Central PMCID: PMC2648874.

31. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18. Epub 2006/05/03. PubMed Central PMCID: PMC2547473. doi: 10.1086/503914 16652319

32. Truong HM, Berrey MM, Shea T, Diem K, Corey L. Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. J Acquir Immune Defic Syndr. 2002;29(3):232–43 11873072

33. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20(7):995–1002 doi: 10.1097/01.aids.0000222071.60620.1d 16603851

34. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192(1):24–9 doi: 10.1086/430742 15942890

35. Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis. 2010;50(10):1405–14. doi: 10.1086/652151 20384494

36. Wagner BG, Garcia-Lerma JG, Blower S. Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks. Sci Rep. 2012;2 : 320. Epub 2012/03/21. doi: 10.1038/srep00320 22432052; PubMed Central PMCID: PMC3307053.

37. Eshleman SH, Lie Y, Hoover DR, Chen S, Hudelson SE, Fiscus SA, et al. Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naive Malawian women. J Infect Dis. 2006;193(11):1512–5 doi: 10.1086/503810 16652278

38. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687–93. doi: 10.1086/590501 18662132

39. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82(11):5510–8 doi: 10.1128/JVI.02579-07 18353964

40. Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS. 1998;12(15):F181–9 9814860

41. Lafeuillade A, Solas C, Chadapaud S, Hittinger G, Poggi C, Lacarelle B. HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. J Acquir Immune Defic Syndr. 2003;32(4):462–4 12640207.

42. Zhang H, Dornadula G, Beumont M, Livornese L Jr., Van Uitert B, Henning K, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998;339(25):1803–9 doi: 10.1056/NEJM199812173392502 9854115

43. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA. 2011;108(50):20166–71. PubMed Central PMCID: PMCPMC3250168. doi: 10.1073/pnas.1110064108 22135472

44. Yang WL, Kouyos R, Scherrer AU, Boni J, Shah C, Yerly S, et al. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. J Infect Dis. 2015;212(1):28–38. doi: 10.1093/infdis/jiv012 25576600